A Study Validates THI’s Biorepository as a Global Leader in Long-Term Sample Preservation and Quality Assurance

The Texas Heart Institute (THI) proudly announces a significant achievement for its Biorepository and Biospecimen Profiling Core (BRC) with the publication of studies demonstrating the exceptional quality of biospecimens stored in its inventory. This milestone underscores THI’s dedication to advancing biomedical research through rigorous standards, state-of-the-art storage techniques, and a commitment to quality assurance.

The published research assessed the integrity of bone marrow-derived mesenchymal stromal cells (BM-MSCs) that had been cryopreserved for over five years. Using a series of meticulous evaluations—including cell viability, DNA and RNA integrity, population doubling time, and sterility—the study confirmed that the quality of these long-term stored samples remained on par with freshly preserved controls. The findings underscore the effectiveness of THI-BRC’s standardized protocols and compliance with the College of American Pathologists (CAP) accreditation standards.

“This publication validates our biorepository’s ability to maintain the integrity of biospecimens over extended periods, ensuring they remain valuable resources for advancing biomedical research,” said Camila Hochman-Mendez, PhD, Director of the Biorepository and Biospecimen Profiling Core. “Our commitment to excellence reflects The Texas Heart Institute’s mission to pioneer groundbreaking solutions for the benefit of patients worldwide.”

Key Highlights of the Study

• High Sample Integrity: BM-MSCs cryopreserved for over five years retained robust viability, RNA/DNA integrity, and functional capabilities.
• Rigorous Quality Control: Zero repeated deficiencies were recorded during CAP inspections over the past seven years, reflecting the reliability of THI-BRC’s protocols.
• Scientific Contribution: The study sets a benchmark for biorepositories globally, showcasing THI-BRC as a leader in long-term sample preservation and quality assurance.
• Biorepositories play a crucial role in advancing biomedical innovation by providing high-quality biospecimens for use in research and clinical studies. The THI-BRC’s achievement not only ensures the success of ongoing research but also paves the way for future discoveries in regenerative medicine, cell therapies, and personalized medicine.

Biorepositories are vital to biomedical innovation, providing high-quality biospecimens for research and clinical studies. The success of THI-BRC’s rigorous protocols not only supports ongoing research but also lays the foundation for future breakthroughs in regenerative medicine, cell therapies, and personalized medicine.

“This accomplishment reflects our unwavering commitment to scientific excellence,” added Joseph G. Rogers, MD, President and CEO of The Texas Heart Institute. “By ensuring the highest quality biospecimens, our biorepository is advancing discoveries that will ultimately improve care for patients around the world.”

The full manuscript, titled Quality Assessment of Long-Term Cryopreserved Human Bone-Derived Marrow Mesenchymal Stromal Cell Samples: Experience from the Texas Heart Institute Biorepository and Biospecimen Profiling Core, is available in Biopreservation and Biobanking (Read Here).

For more information about the Texas Heart Institute Biorepository and Biospecimen Profiling Core, please visit www.texasheart.org/research/regenerative-medicine-research/brc/.